Chinese researchers have utilized LEAPER to restore functional enzyme activity in cells from patients with Hurler syndrome. They have claimed that LEAPER could have the potential to treat almost half of all known hereditary disorders.
Highly specific editing efficiencies of up to 80% can be achieved when LEAPER editing using arRNA151 is delivered via a plasmid or viral vector or as a synthetic oligonucleotide, though this efficiency varied significantly across cell types.  Based on these preliminary results, LEAPER may have the most therapeutic promise with no production of functional protein but if a partial restoration of protein expression would provide therapeutic benefit. For example, in human cells with defective α-L-iduronidase (IDUA) expression in cells from patients with IDUA-defective Hurler syndrome, LEAPER resulted in a W53X truncation mutant of p53 being edited using arRNA151 to achieve a "normal" p53 translation and functional p53-mediated transcriptional responses.